Back to Search Start Over

Prevalence of persistent SARS-CoV-2 in a large community surveillance study.

Authors :
Ghafari M
Hall M
Golubchik T
Ayoubkhani D
House T
MacIntyre-Cockett G
Fryer HR
Thomson L
Nurtay A
Kemp SA
Ferretti L
Buck D
Green A
Trebes A
Piazza P
Lonie LJ
Studley R
Rourke E
Smith DL
Bashton M
Nelson A
Crown M
McCann C
Young GR
Santos RAND
Richards Z
Tariq MA
Cahuantzi R
Barrett J
Fraser C
Bonsall D
Walker AS
Lythgoe K
Source :
Nature [Nature] 2024 Feb; Vol. 626 (8001), pp. 1094-1101. Date of Electronic Publication: 2024 Feb 21.
Publication Year :
2024

Abstract

Persistent SARS-CoV-2 infections may act as viral reservoirs that could seed future outbreaks <superscript>1-5</superscript> , give rise to highly divergent lineages <superscript>6-8</superscript> and contribute to cases with post-acute COVID-19 sequelae (long COVID) <superscript>9,10</superscript> . However, the population prevalence of persistent infections, their viral load kinetics and evolutionary dynamics over the course of infections remain largely unknown. Here, using viral sequence data collected as part of a national infection survey, we identified 381 individuals with SARS-CoV-2 RNA at high titre persisting for at least 30 days, of which 54 had viral RNA persisting at least 60 days. We refer to these as 'persistent infections' as available evidence suggests that they represent ongoing viral replication, although the persistence of non-replicating RNA cannot be ruled out in all. Individuals with persistent infection had more than 50% higher odds of self-reporting long COVID than individuals with non-persistent infection. We estimate that 0.1-0.5% of infections may become persistent with typically rebounding high viral loads and last for at least 60 days. In some individuals, we identified many viral amino acid substitutions, indicating periods of strong positive selection, whereas others had no consensus change in the sequences for prolonged periods, consistent with weak selection. Substitutions included mutations that are lineage defining for SARS-CoV-2 variants, at target sites for monoclonal antibodies and/or are commonly found in immunocompromised people <superscript>11-14</superscript> . This work has profound implications for understanding and characterizing SARS-CoV-2 infection, epidemiology and evolution.<br /> (© 2024. The Author(s).)

Details

Language :
English
ISSN :
1476-4687
Volume :
626
Issue :
8001
Database :
MEDLINE
Journal :
Nature
Publication Type :
Academic Journal
Accession number :
38383783
Full Text :
https://doi.org/10.1038/s41586-024-07029-4